Evaluation of surrogate inflammatory markers for optimizing inhaled corticosteroid therapy in a real-life clinical setting

Stephen J. Fowler; Nicola J. Syme-Grant; Frank A. Carey; Brian J. Lipworth

doi:10.1046/j.1440-1592.2003.00280.x

Evaluation of surrogate inflammatory markers for optimizing inhaled corticosteroid therapy in a real-life clinical setting

Stephen J. Fowler, Nicola J. Syme-Grant, Frank A. Carey, Brian J. Lipworth^*

^*Corresponding author for this work

Division of Immunology, Immunity to Infection and Respiratory Medicine

University of Dundee

Research output: Contribution to journal › Article › peer-review

Abstract

Background: To determine the effects of 1 months treatment with optimized high-dose inhaled corticosteroid on surrogate markers of airways inflammation, as well as lung function, in a clinical setting. Methods: Nine steroid-treated asthmatics (mean dose 778 μg/day) with uncontrolled disease were all switched to 1 months treatment with 2000 μg/day inhaled beclomethasone dipropionate dry powder. Serial spot clinic measurements were made of pre- and post-treatment effects on sputum eosinophils, serum eosinophil cationic protein (ECP), bronchial hyper-responsiveness (BHR) to methacholine, exhaled nitric oxide (NO), spirometry and domiciliary peak expiratory flow rate (PEF), symptom score and reliever use. Results: Optimization of inhaled corticosteroid treatment had further significant (P < 0.05) beneficial effects only on sputum eosinophils, BHR, symptom score and morning PEF. Furthermore, treatment decreased the eosinophil count in all cases. Conclusions: Serial clinic measurements of sputum eosinophils and BHR may provide additional information on asthmatic inflammation to assess the response to inhaled steroids in patients who have uncontrolled asthma.

Original language	English
Pages (from-to)	71-75
Number of pages	5
Journal	Allergology International
Volume	52
Issue number	2
DOIs	https://doi.org/10.1046/j.1440-1592.2003.00280.x
Publication status	Published - Jun 2003

Keywords

Airway inflammation
Asthma
Bronchial hyperreactivity
Inhaled corticosteroids
Sputum eosinophils

Research Beacons, Institutes and Platforms

Manchester Institute of Biotechnology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1046/j.1440-1592.2003.00280.x

Cite this

@article{6ef7f785f950455c9d919dc7b7fa4cb0,

title = "Evaluation of surrogate inflammatory markers for optimizing inhaled corticosteroid therapy in a real-life clinical setting",

abstract = "Background: To determine the effects of 1 months treatment with optimized high-dose inhaled corticosteroid on surrogate markers of airways inflammation, as well as lung function, in a clinical setting. Methods: Nine steroid-treated asthmatics (mean dose 778 μg/day) with uncontrolled disease were all switched to 1 months treatment with 2000 μg/day inhaled beclomethasone dipropionate dry powder. Serial spot clinic measurements were made of pre- and post-treatment effects on sputum eosinophils, serum eosinophil cationic protein (ECP), bronchial hyper-responsiveness (BHR) to methacholine, exhaled nitric oxide (NO), spirometry and domiciliary peak expiratory flow rate (PEF), symptom score and reliever use. Results: Optimization of inhaled corticosteroid treatment had further significant (P < 0.05) beneficial effects only on sputum eosinophils, BHR, symptom score and morning PEF. Furthermore, treatment decreased the eosinophil count in all cases. Conclusions: Serial clinic measurements of sputum eosinophils and BHR may provide additional information on asthmatic inflammation to assess the response to inhaled steroids in patients who have uncontrolled asthma.",

keywords = "Airway inflammation, Asthma, Bronchial hyperreactivity, Inhaled corticosteroids, Sputum eosinophils",

author = "Fowler, {Stephen J.} and Syme-Grant, {Nicola J.} and Carey, {Frank A.} and Lipworth, {Brian J.}",

year = "2003",

month = jun,

doi = "10.1046/j.1440-1592.2003.00280.x",

language = "English",

volume = "52",

pages = "71--75",

journal = "Allergology International",

issn = "1323-8930",

publisher = "Japanese Society of Allergology",

number = "2",

}

TY - JOUR

T1 - Evaluation of surrogate inflammatory markers for optimizing inhaled corticosteroid therapy in a real-life clinical setting

AU - Fowler, Stephen J.

AU - Syme-Grant, Nicola J.

AU - Carey, Frank A.

AU - Lipworth, Brian J.

PY - 2003/6

Y1 - 2003/6

N2 - Background: To determine the effects of 1 months treatment with optimized high-dose inhaled corticosteroid on surrogate markers of airways inflammation, as well as lung function, in a clinical setting. Methods: Nine steroid-treated asthmatics (mean dose 778 μg/day) with uncontrolled disease were all switched to 1 months treatment with 2000 μg/day inhaled beclomethasone dipropionate dry powder. Serial spot clinic measurements were made of pre- and post-treatment effects on sputum eosinophils, serum eosinophil cationic protein (ECP), bronchial hyper-responsiveness (BHR) to methacholine, exhaled nitric oxide (NO), spirometry and domiciliary peak expiratory flow rate (PEF), symptom score and reliever use. Results: Optimization of inhaled corticosteroid treatment had further significant (P < 0.05) beneficial effects only on sputum eosinophils, BHR, symptom score and morning PEF. Furthermore, treatment decreased the eosinophil count in all cases. Conclusions: Serial clinic measurements of sputum eosinophils and BHR may provide additional information on asthmatic inflammation to assess the response to inhaled steroids in patients who have uncontrolled asthma.

AB - Background: To determine the effects of 1 months treatment with optimized high-dose inhaled corticosteroid on surrogate markers of airways inflammation, as well as lung function, in a clinical setting. Methods: Nine steroid-treated asthmatics (mean dose 778 μg/day) with uncontrolled disease were all switched to 1 months treatment with 2000 μg/day inhaled beclomethasone dipropionate dry powder. Serial spot clinic measurements were made of pre- and post-treatment effects on sputum eosinophils, serum eosinophil cationic protein (ECP), bronchial hyper-responsiveness (BHR) to methacholine, exhaled nitric oxide (NO), spirometry and domiciliary peak expiratory flow rate (PEF), symptom score and reliever use. Results: Optimization of inhaled corticosteroid treatment had further significant (P < 0.05) beneficial effects only on sputum eosinophils, BHR, symptom score and morning PEF. Furthermore, treatment decreased the eosinophil count in all cases. Conclusions: Serial clinic measurements of sputum eosinophils and BHR may provide additional information on asthmatic inflammation to assess the response to inhaled steroids in patients who have uncontrolled asthma.

KW - Airway inflammation

KW - Asthma

KW - Bronchial hyperreactivity

KW - Inhaled corticosteroids

KW - Sputum eosinophils

UR - http://www.scopus.com/inward/record.url?scp=0038176437&partnerID=8YFLogxK

U2 - 10.1046/j.1440-1592.2003.00280.x

DO - 10.1046/j.1440-1592.2003.00280.x

M3 - Article

AN - SCOPUS:0038176437

SN - 1323-8930

VL - 52

SP - 71

EP - 75

JO - Allergology International

JF - Allergology International

IS - 2

ER -

Evaluation of surrogate inflammatory markers for optimizing inhaled corticosteroid therapy in a real-life clinical setting

Abstract

Keywords

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this